27/05/2026
When to cut losses on non-performing brands
One of the hardest decisions for any pharma startup is this:
👉 When should we stop pushing a brand?
Emotionally, founders want every brand to succeed.
Practically, that is not possible.
Some brands simply don’t work in the market — and continuing to invest in them drains time, money, and team energy.
The biggest mistake companies make is waiting too long.
They keep hoping:
⭐ “Maybe next month it will improve”
⭐ “Let’s give one more scheme”
⭐ “Let’s push harder”
But without real market signals, this becomes resource wastage.
Here are clear signs that a brand may not be working.
⭐ No doctor interest even after multiple visits
If doctors are not even willing to try, positioning is weak.
⭐ No repeat demand
Trial happened, but no continuation means poor acceptance.
⭐ Weak differentiation
Brand does not stand out vs competitors.
⭐ Low MR confidence
If MRs themselves don’t believe in the brand, conversion drops.
⭐ High effort, low output
Too much time invested but minimal results.
Now the key question:
👉 What should you do?
⭐ Don’t take emotional decisions
Business decisions must be data-driven.
⭐ Evaluate honestly
Check real doctor feedback, not assumptions.
⭐ Pause instead of completely stopping
You can always restart later with better strategy.
⭐ Redirect resources
Focus on brands that are showing traction.
⭐ Learn from failure
Every weak brand teaches something about the market.
Important mindset:
Stopping a weak brand is not failure.
It is smart prioritization.
Because in startups:
⭐ Limited time
⭐ Limited money
⭐ Limited manpower
You cannot afford to waste resources.
Strong companies grow by focusing on what works — not by holding onto what doesn’t.
👉 Do you hold onto weak brands too long — or take timely decisions?